Merck Historical Cash Flow

MRK Stock  USD 130.06  0.17  0.13%   
Analysis of Merck cash flow over time is an excellent tool to project Merck Company future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 3.1 B or Other Non Cash Items of 12.8 B as it is a great indicator of Merck ability to facilitate future growth, repay debt on time or pay out dividends.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Merck Company latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Merck Company is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

About Merck Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Merck balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Merck's non-liquid assets can be easily converted into cash.

Merck Cash Flow Chart

Merck Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Merck Company Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Merck's Cash And Cash Equivalents Changes is quite stable compared to the past year. Cash Flows Other Operating is expected to rise to about 17.5 B this year, although the value of Change In Cash is projected to rise to (5.6 B).

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Merck Company to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Merck operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Merck Company financial statement analysis. It represents the amount of money remaining after all of Merck Company operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most accounts from Merck's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
At this time, Merck's Cash And Cash Equivalents Changes is quite stable compared to the past year. Cash Flows Other Operating is expected to rise to about 17.5 B this year, although the value of Change In Cash is projected to rise to (5.6 B).

Merck cash flow statement Correlations

-0.120.070.03-0.41-0.19-0.480.450.27-0.06-0.15-0.01-0.070.46-0.33-0.13-0.19-0.010.330.460.27-0.27
-0.120.040.060.37-0.20.24-0.33-0.50.04-0.13-0.33-0.15-0.220.310.230.04-0.05-0.79-0.28-0.320.19
0.070.040.49-0.2-0.490.07-0.060.00.30.48-0.04-0.230.470.260.680.310.450.060.43-0.230.12
0.030.060.49-0.030.250.430.120.380.470.720.670.030.33-0.32-0.15-0.07-0.04-0.080.240.49-0.08
-0.410.37-0.2-0.030.120.2-0.52-0.470.03-0.06-0.390.64-0.530.12-0.080.23-0.23-0.61-0.11-0.320.61
-0.19-0.2-0.490.250.120.62-0.060.170.090.520.540.15-0.36-0.25-0.830.02-0.2-0.15-0.350.450.14
-0.480.240.070.430.20.62-0.37-0.220.160.710.37-0.02-0.320.03-0.250.370.03-0.53-0.43-0.010.35
0.45-0.33-0.060.12-0.52-0.06-0.370.23-0.56-0.170.34-0.420.71-0.25-0.31-0.14-0.090.470.630.63-0.66
0.27-0.50.00.38-0.470.17-0.220.230.550.180.730.160.17-0.57-0.2-0.6-0.050.57-0.030.58-0.57
-0.060.040.30.470.030.090.16-0.560.550.410.330.35-0.28-0.240.17-0.32-0.080.06-0.360.070.08
-0.15-0.130.480.72-0.060.520.71-0.170.180.410.51-0.060.060.02-0.140.320.25-0.110.020.190.28
-0.01-0.33-0.040.67-0.390.540.370.340.730.330.51-0.040.16-0.56-0.48-0.31-0.170.27-0.090.76-0.48
-0.07-0.15-0.230.030.640.15-0.02-0.420.160.35-0.06-0.04-0.44-0.52-0.16-0.25-0.21-0.14-0.14-0.010.25
0.46-0.220.470.33-0.53-0.36-0.320.710.17-0.280.060.16-0.44-0.130.17-0.120.40.320.680.23-0.43
-0.330.310.26-0.320.12-0.250.03-0.25-0.57-0.240.02-0.56-0.52-0.130.420.640.26-0.20.06-0.60.43
-0.130.230.68-0.15-0.08-0.83-0.25-0.31-0.20.17-0.14-0.48-0.160.170.420.150.47-0.030.05-0.680.08
-0.190.040.31-0.070.230.020.37-0.14-0.6-0.320.32-0.31-0.25-0.120.640.150.05-0.150.22-0.420.57
-0.01-0.050.45-0.04-0.23-0.20.03-0.09-0.05-0.080.25-0.17-0.210.40.260.470.05-0.20.08-0.450.11
0.33-0.790.06-0.08-0.61-0.15-0.530.470.570.06-0.110.27-0.140.32-0.2-0.03-0.15-0.20.330.38-0.46
0.46-0.280.430.24-0.11-0.35-0.430.63-0.03-0.360.02-0.09-0.140.680.060.050.220.080.330.25-0.05
0.27-0.32-0.230.49-0.320.45-0.010.630.580.070.190.76-0.010.23-0.6-0.68-0.42-0.450.380.25-0.51
-0.270.190.12-0.080.610.140.35-0.66-0.570.080.28-0.480.25-0.430.430.080.570.11-0.46-0.05-0.51
Click cells to compare fundamentals

Merck Account Relationship Matchups

Merck cash flow statement Accounts

201920202021202220232024 (projected)
Sale Purchase Of Stock(4.8B)(1.3B)(840M)384M(1.3B)(1.4B)
Change To Inventory(508M)(855M)(674M)(161M)(816M)(775.2M)
Change In Cash2.0B(1.8B)14M4.6B(5.9B)(5.6B)
Free Cash Flow10.0B5.6B9.7B14.7B9.1B6.7B
Change In Working Capital(2.1B)(4.6B)(3.8B)(2.8B)(2.2B)(2.1B)
Begin Period Cash Flow8.0B9.9B8.2B8.2B12.8B13.4B
Other Cashflows From Financing Activities1.6B(436M)8.7B144M8.0B8.4B
Depreciation3.7B3.6B3.2B3.9B3.9B3.1B
Other Non Cash Items2.2B4.3B1.7B4.5B12.2B12.8B
Dividends Paid5.7B6.2B6.6B7.0B(7.4B)(7.1B)
Capital Expenditures3.5B4.7B4.4B4.4B3.9B2.2B
Total Cash From Operating Activities13.4B10.3B14.1B19.1B13.0B8.8B
Net Income9.8B7.1B12.4B14.5B365M346.8M
Total Cash From Financing Activities(8.9B)(2.8B)2.6B(9.1B)(4.8B)(5.1B)
End Period Cash Flow9.9B8.2B8.2B12.8B6.9B6.2B
Stock Based Compensation417M475M479M541M645M346.8M
Change To Liabilities(1.8B)(307M)626M(504M)(453.6M)(476.3M)
Change To Netincome2.1B1.5B2.8B2.0B2.3B2.4B
Change To Account Receivables294M(1.0B)(2.0B)(644M)(1.1B)(1.1B)
Other Cashflows From Investing Activities(4.6B)(6.5B)(13.1B)(89M)(80.1M)(84.1M)
Total Cashflows From Investing Activities(2.6B)(9.4B)(16.6B)(5.0B)(14.1B)(13.4B)
Investments5.4B1.7B1.0B(483M)(15.9B)(15.1B)
Change Receivables294M(1.0B)(2.0B)(644M)(579.6M)(550.6M)
Net Borrowings1.2B5.0B1.6B(2.3B)(2.0B)(1.9B)
Cash And Cash Equivalents Changes2.0B(2.0B)(202M)5.0B4.5B4.7B
Cash Flows Other Operating(32M)234M10.2B14.5B16.6B17.5B
Change To Operating Activities107M(4.0B)(997M)(2.1B)(1.9B)(2.0B)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
CEOs Directory
Screen CEOs from public companies around the world
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Transaction History
View history of all your transactions and understand their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.685
Dividend Share
2.96
Earnings Share
0.9
Revenue Per Share
24.215
Quarterly Revenue Growth
0.089
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.